Study Of Single Ascending Doses Of PBL 1427 In Healthy Volunteers

Summary

PBL 1427 is a Dipeptidyl peptidase (DPP)-IV inhibitor being developed for treatment of type 2 diabetes. Although a number of DPP-IV inhibitors have been described, there still exists a need for new DPP-IV inhibitors that have better half-life, advantageous potency, stability and selectivity, less toxicity and/or better pharmacodynamic properties.

Timeline

Start

2012-07

Primary completion

2013-07

Completion

2013-09

Drugs

Indications